Showing 641 - 660 results of 134,001 for search '(( 2 we decrease ) OR ( 5 ((((nn decrease) OR (fold decrease))) OR (a decrease)) ))', query time: 1.92s Refine Results
  1. 641
  2. 642

    S1 data_Hazen Main and Blister 2017 absolute diatom counts from Contrasting the ecological effects of decreasing ice cover versus accelerated glacial melt on the High Arctic's larg... by Neal Michelutti (688828)

    Published 2020
    “…Subfossil diatom assemblages in all cores show two major shifts over the past approximately 200 years including: (i) a proliferation of pioneering, benthic taxa at approximately 1900 CE from previously depauperate populations; and (ii) a rise in planktonic taxa beginning at approximately 1980 CE to present-day dominance. …”
  3. 643
  4. 644
  5. 645
  6. 646
  7. 647

    Downregulation of DOM decreases the abundance of PER and TIM. by Zhenxing Liu (399809)

    Published 2019
    “…Downregulation of DOM decreased PER levels at CT1-5 and CT17-21. (Scale bar: 50 um.) …”
  8. 648

    Dramatic Lockdown Fossil Fuel CO<sub>2</sub> Decrease Detected by Citizen Science-Supported Atmospheric Radiocarbon Observations by Jocelyn C. Turnbull (6083705)

    Published 2022
    “…The local fossil fuel CO<sub>2</sub> mole fractions during lockdown were compared with a “normal” nonlockdown period. …”
  9. 649
  10. 650

    Overview of the WeARTolerance program. by Ana Beato (20489933)

    Published 2024
    “…The quantitative results from Phase 1 demonstrated a decreasing trend in all primary outcomes. In phase 2, participants acknowledged the activities’ relevance, reported overall satisfaction with the program, and showed great enthusiasm and willingness to learn more. …”
  11. 651
  12. 652
  13. 653

    Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease by Sandra L. Dabora (206838)

    Published 2011
    “…<div><h3>Background</h3><p>Tuberous sclerosis (TSC) related tumors are characterized by constitutively activated mTOR signaling due to mutations in <em>TSC1</em> or <em>TSC2</em>.</p> <h3>Methods</h3><p>We completed a phase 2 multicenter trial to evaluate the efficacy and tolerability of the mTOR inhibitor, sirolimus, for the treatment of kidney angiomyolipomas.…”
  14. 654
  15. 655
  16. 656
  17. 657
  18. 658

    The Transition from a Compensatory Increase to a Decrease in C-peptide During the Progression to Type 1 Diabetes and Its Relation to Risk by Heba M Ismail (9568748)

    Published 2022
    “…Conclusions</p> <p>A transition from an increase to a decrease in AUC C-peptide approximately 1.5 years pre-diagnosis was validated in two independent cohorts. …”
  19. 659
  20. 660